Lv3
380 积分 2024-12-10 加入
A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation
6天前
已完结
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs
1个月前
已完结
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
1个月前
已完结
Systematic review of cost-effectiveness of Chinese PD-1/PD-L1 inhibitors as first-line treatment for hepatocellular carcinoma
1个月前
已完结
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
2个月前
已完结
Immune checkpoint blockers plus chemotherapy as the first-line treatment for advanced or metastatic squamous non-small-cell lung carcinoma: a network meta-analysis and economic evaluation
2个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
5个月前
已完结
Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer
5个月前
已完结
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11)
6个月前
已完结
皖公网安备34019202002308
